RxDoctor Payments Data

Mrudula Munagala, MD

Advanced Heart Failure and Transplant Cardiology · Miami, FLNPI 1124280789

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 26.1% of the total. Reporting peaked in 2019 at $33,929 and has fallen 96.0% since, to $1,374 in 2025.

$67,358in general payments, 2019–2025

Across 246 payments — averaging $273.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$18K
  • Sanofi Pasteur Inc.$14K
  • Akcea Therapeutics, Inc.$13K
  • United Therapeutics Corporation$6K
  • Bayer$5K
  • Actelion Pharmaceuticals US, Inc.$5K
  • plus $7K from 17 others
$12,065in research payments, 2019–2025

Across 4 payments — averaging $3016.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$12K

What the payments were for

  • Consulting fees$31,44947%
  • Speaking & faculty fees$22,41333%
  • Travel & lodging$6,0809%
  • Food & beverage$7,29111%
  • Education$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,358 in reported general payments places this provider in the 75th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

See all advanced heart failure and transplant cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$47,766
Medicare patients
56
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan48$591,846
VyndamaxTafamidis12$346,597
AdempasRiociguat11$145,422
EntrestoSacubitril/Valsartan26$40,057
EliquisApixaban17$21,428
FarxigaDapagliflozin Propanediol14$14,089
Sildenafil Citrate17$3,189
Tacrolimus17$2,019
Mycophenolate Mofetil11$1,426
Bumetanide24$651
Warfarin Sodium37$492
Isosorbide Dinitrate11$342
Rosuvastatin Calcium38$342
Potassium Chloride15$293
Carvedilol52$288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$4,908$591,84648 claims
PfizerVyndamax, Eliquis$440$368,02529 claims
BayerAdempas$5,016$145,42211 claims
NovartisEntresto$174$40,05726 claims
AstraZenecaFarxiga$101$14,08914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.

Other advanced heart failure and transplant cardiology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →